AI Engines For more Details: Perplexity Kagi Labs You
Antidote for Poisoning: Fomepizole is used as an antidote to treat poisoning caused by ingestion or exposure to methanol (wood alcohol) and ethylene glycol (antifreeze). These substances are toxic when ingested and can cause severe metabolic acidosis, neurological impairment, and even death if not treated promptly.
Inhibition of Alcohol Dehydrogenase: Fomepizole works by inhibiting the enzyme alcohol dehydrogenase, which is responsible for the metabolism of methanol and ethylene glycol into their toxic byproducts. By inhibiting this enzyme, fomepizole prevents the formation of toxic metabolites, allowing the body to eliminate the poison safely.
Rapid Onset of Action: Fomepizole acts quickly to halt the metabolism of methanol and ethylene glycol, thereby preventing the accumulation of toxic metabolites in the body. Early administration of fomepizole is crucial for effective treatment and prevention of severe complications.
Alternative to Ethanol: Fomepizole is often used as an alternative to ethanol (drinking alcohol) in the treatment of methanol and ethylene glycol poisoning. Unlike ethanol, fomepizole does not cause intoxication and can be administered more easily and safely in a medical setting.
Monitoring and Supportive Care: Treatment with fomepizole requires close monitoring of metabolic parameters such as blood pH, electrolytes, and renal function. Supportive care, including intravenous fluids, correction of electrolyte imbalances, and hemodialysis, may also be necessary to manage complications of poisoning.
Adverse Effects: Common side effects of fomepizole may include headache, nausea, vomiting, dizziness, and injection site reactions. These side effects are usually mild and transient.
Contraindications: Fomepizole is contraindicated in individuals with known hypersensitivity to the medication. It should be used with caution in patients with impaired renal function or hepatic dysfunction.
Pregnancy and Lactation: The safety of fomepizole use during pregnancy and lactation has not been well studied. Pregnant or breastfeeding individuals should consult with their healthcare provider regarding the risks and benefits of fomepizole therapy.
Pediatric Use: Fomepizole is approved for use in pediatric patients, including infants and children, for the treatment of methanol and ethylene glycol poisoning. Dosing adjustments may be necessary based on the child's age, weight, and medical condition.
Drug Interactions: Fomepizole may interact with other medications, including drugs that affect liver metabolism or renal function. Patients should inform their healthcare provider about all medications and supplements they are taking before starting fomepizole therapy.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0 | 0 | |
| Acne | 0.2 | -0.2 | |
| ADHD | 1.4 | 1.4 | |
| Age-Related Macular Degeneration and Glaucoma | 0.2 | 0.1 | 1 |
| Allergic Rhinitis (Hay Fever) | 0.5 | 0.8 | -0.6 |
| Allergies | 1.4 | 1.1 | 0.27 |
| Allergy to milk products | 0.6 | 0.3 | 1 |
| Alopecia (Hair Loss) | 0.6 | 0.6 | |
| Alzheimer's disease | 0.9 | 1.1 | -0.22 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.6 | 0.4 | 0.5 |
| Ankylosing spondylitis | 1.1 | 0.5 | 1.2 |
| Anorexia Nervosa | 0.1 | 0.6 | -5 |
| Antiphospholipid syndrome (APS) | 0.3 | 0 | 0 |
| Asthma | 0.3 | 0.4 | -0.33 |
| Atherosclerosis | 0.6 | 0.5 | 0.2 |
| Atrial fibrillation | 1.1 | 0.5 | 1.2 |
| Autism | 2.6 | 2.1 | 0.24 |
| Barrett esophagus cancer | 0.1 | 0.1 | 0 |
| benign prostatic hyperplasia | 0 | 0 | |
| Bipolar Disorder | 0.5 | 0.4 | 0.25 |
| Brain Trauma | 0.3 | 0.2 | 0.5 |
| Carcinoma | 1.2 | 1.1 | 0.09 |
| Celiac Disease | 0.5 | 1.3 | -1.6 |
| Cerebral Palsy | 0.5 | 0.5 | 0 |
| Chronic Fatigue Syndrome | 1.5 | 1.5 | 0 |
| Chronic Kidney Disease | 0.4 | 0.2 | 1 |
| Chronic Lyme | 0.2 | -0.2 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.4 | 0.1 | 3 |
| Chronic Urticaria (Hives) | 0.4 | 0.1 | 3 |
| Coagulation / Micro clot triggering bacteria | 0.3 | 0.4 | -0.33 |
| Colorectal Cancer | 1.1 | 0.3 | 2.67 |
| Constipation | 0.2 | 0.1 | 1 |
| Coronary artery disease | 0.5 | 0.2 | 1.5 |
| COVID-19 | 2.9 | 4 | -0.38 |
| Crohn's Disease | 1.7 | 1.3 | 0.31 |
| cystic fibrosis | 0.1 | 0.4 | -3 |
| deep vein thrombosis | 0.1 | 0.4 | -3 |
| Depression | 3.2 | 2 | 0.6 |
| Dermatomyositis | 0.1 | 0.2 | -1 |
| Eczema | 0.3 | 0.5 | -0.67 |
| Endometriosis | 0.8 | 0.5 | 0.6 |
| Eosinophilic Esophagitis | 0.1 | -0.1 | |
| Epilepsy | 0.7 | 0.6 | 0.17 |
| Fibromyalgia | 0.6 | 0.4 | 0.5 |
| Functional constipation / chronic idiopathic constipation | 1.3 | 1.4 | -0.08 |
| gallstone disease (gsd) | 0.8 | 0.2 | 3 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 0.2 | 0 |
| Generalized anxiety disorder | 0.3 | 0.6 | -1 |
| giant cell arteritis | 0.1 | -0.1 | |
| Glioblastoma | 0.1 | -0.1 | |
| Graves' disease | 0.6 | 0.5 | 0.2 |
| Halitosis | 0.3 | 0.1 | 2 |
| Hashimoto's thyroiditis | 0.7 | 0.3 | 1.33 |
| Hidradenitis Suppurativa | 0.1 | 0.1 | 0 |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.9 | 0.1 | 8 |
| hypercholesterolemia (High Cholesterol) | 0.2 | 0.1 | 1 |
| hyperglycemia | 0 | 0.6 | 0 |
| Hyperlipidemia (High Blood Fats) | 0.4 | 0.2 | 1 |
| hypersomnia | 0.1 | -0.1 | |
| hypertension (High Blood Pressure | 1 | 1.3 | -0.3 |
| Hypothyroidism | 0.2 | -0.2 | |
| Hypoxia | 0.3 | 0.3 | |
| IgA nephropathy (IgAN) | 0.5 | -0.5 | |
| Inflammatory Bowel Disease | 1 | 2.3 | -1.3 |
| Insomnia | 0.3 | 0.2 | 0.5 |
| Intelligence | 0.1 | 0.1 | |
| Intracranial aneurysms | 0.6 | 0.2 | 2 |
| Irritable Bowel Syndrome | 1.9 | 0.9 | 1.11 |
| Liver Cirrhosis | 1.4 | 1.2 | 0.17 |
| Long COVID | 2.4 | 2.8 | -0.17 |
| Low bone mineral density | 0.1 | -0.1 | |
| Lung Cancer | 0.9 | 0.5 | 0.8 |
| ME/CFS with IBS | 0.5 | 0.8 | -0.6 |
| ME/CFS without IBS | 0.4 | 1 | -1.5 |
| Menopause | 0.8 | 0.8 | |
| Metabolic Syndrome | 2.8 | 2.2 | 0.27 |
| Mood Disorders | 4.2 | 2 | 1.1 |
| multiple chemical sensitivity [MCS] | 0.4 | 0.1 | 3 |
| Multiple Sclerosis | 1.3 | 1.2 | 0.08 |
| Multiple system atrophy (MSA) | 0.2 | 0.5 | -1.5 |
| Neuropathy (all types) | 0.2 | 0 | 0 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.1 | 0.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.6 | 1.5 | -1.5 |
| NonCeliac Gluten Sensitivity | 0.2 | -0.2 | |
| Obesity | 3.3 | 1.4 | 1.36 |
| obsessive-compulsive disorder | 1.7 | 0.8 | 1.13 |
| Osteoarthritis | 0.6 | 0.2 | 2 |
| Osteoporosis | 0.7 | 0.3 | 1.33 |
| pancreatic cancer | 0.1 | 0.1 | |
| Parkinson's Disease | 0.7 | 0.8 | -0.14 |
| Polycystic ovary syndrome | 0.7 | 0.9 | -0.29 |
| Postural orthostatic tachycardia syndrome | 0.1 | 0.2 | -1 |
| Premenstrual dysphoric disorder | 0.4 | 0.1 | 3 |
| primary biliary cholangitis | 0.2 | 0.2 | 0 |
| Psoriasis | 1.6 | 0.6 | 1.67 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.7 | 1.1 | 0.55 |
| Rosacea | 0.4 | 0.2 | 1 |
| Schizophrenia | 2.2 | 0.6 | 2.67 |
| scoliosis | 0.2 | -0.2 | |
| Sjögren syndrome | 0.8 | 1.1 | -0.38 |
| Sleep Apnea | 0.5 | 0.3 | 0.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.1 | 0.2 | -1 |
| Stress / posttraumatic stress disorder | 0.8 | 0.6 | 0.33 |
| Systemic Lupus Erythematosus | 0.8 | 0.6 | 0.33 |
| Tic Disorder | 0.3 | 0.5 | -0.67 |
| Tourette syndrome | 0 | 0.2 | 0 |
| Type 1 Diabetes | 0.8 | 0.7 | 0.14 |
| Type 2 Diabetes | 2.7 | 1.4 | 0.93 |
| Ulcerative colitis | 0.8 | 0.9 | -0.13 |
| Unhealthy Ageing | 1.3 | 0.3 | 3.33 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.